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OBJECTIVES We investigated whether the benefits of stent implantation over balloon percutaneous
transluminal coronary angioplasty (PTCA) for treatment of chronic total coronary occlusions
(CTO) are maintained in the long term.
BACKGROUND Several randomized trials have shown that in CTO, stent implantation confers clinical and
angiographic mid-term outcomes superior to those observed after PTCA. However, limited
information on the long-term results of either technique is available.
METHODS Six-year clinical follow-up of patients enrolled in the Gruppo Italiano di Studio sullo Stent
nelle Occlusioni Coronariche (GISSOC) trial was performed by direct visit or telephone
interview. Major adverse cardiac events (MACE), defined as cardiac death, myocardial
infarction, target lesion revascularization (TLR), and anginal status, were recorded.
RESULTS Freedom from MACE at six years was 76.1% in the stent group, compared with 60.4% in the
PTCA group (p 0.0555). This difference was due mainly to TLR-free survival rates (85.1%
vs. 65.5% for the stent and PTCA groups, respectively; p  0.0165). Eleven patients
underwent TLR after the nine-month follow-up visit (stent group: n  5; PTCA group: n
 6); however, in most cases, restenosis of the study occlusion was evident at nine-month
angiography.
CONCLUSIONS This study represents the longest reported clinical follow-up of patients after percutaneous
recanalization of CTO and demonstrates that the superiority of stent implantation over
balloon PTCA is maintained in the long term. Stent and PTCA results appear to remain
stable after nine-month angiographic follow-up. Stent implantation in CTO that can be
recanalized percutaneously is therefore a valuable long-term therapeutic option. (J Am Coll
Cardiol 2003;41:1488–92) © 2003 by the American College of Cardiology Foundation
Patients with chronic total coronary occlusions (CTOs) that
are successfully recanalized by percutaneous transluminal cor-
onary angioplasty (PTCA) show a higher restenosis rate than
that reported for subtotal stenoses (1,2). Several randomized
studies (3–9) have demonstrated that stent implantation after
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successful PTCA of CTO can significantly decrease the
incidence of six-month angiographic restenosis and the need
for target lesion revascularization (TLR). However, very few
data are available on the long-term prognosis of patients
treated by balloon PTCA or stent implantation for CTO. In
this study, we report the clinical outcomes of 110 patients
enrolled in the Gruppo Italiano di Studio sullo Stent nelle
Occlusioni Coronariche (GISSOC) trial (5) after a mean
follow-up of 6.2  2.1 years. Our aim was to determine
whether the benefits of stent implantation over PTCA for
treatment of CTO are maintained in the long term.
METHODS
Patient selection and randomization. The study protocol,
which has previously been described in detail (5), was approved
by the Institutional Review Board at each participating center.
Briefly, patients with angina or inducible ischemia thought to
be caused by a chronic CTO (30 days in duration) were
selected for the study. A total occlusion was defined as the
absence of a discernible luminal channel with Thrombolysis in
Myocardial Infarction (TIMI) flow grade 0 or 1 (10).
Exclusion criteria included 30 days’ duration of the
total occlusion, acute myocardial infarction (MI) within 30
days or chest pain at rest within seven days, contraindication
to aspirin or warfarin sodium, ineligibility for bypass sur-
gery, previous PTCA of the occluded vessel, vessel diameter
3 mm, severe vessel tortuosity, and lesion length 13
mm. The target CTO was treated by conventional balloon
angioplasty. In case of successful recanalization, defined as
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restoration of anterograde TIMI flow grade 2 or 3 with a
residual stenosis 50% of the luminal diameter by visual
estimation, the patients were randomized to stent implan-
tation or no additional treatment.
Procedural protocol. All patients received aspirin (150 to
325 mg/day) starting at least 24 h before PTCA. During the
procedure, heparin was given to maintain an activated
clotting time 250 s. In patients assigned to stent implan-
tation, the articulated Palmaz-Schatz stent (Cordis, War-
ren, New Jersey) was manually crimped onto a conventional
balloon catheter and deployed to the target site. Four to
eight hours after hemostasis at the site of arterial access was
achieved, oral warfarin and heparin infusions were begun.
Heparin infusion was continued until an International
Normalized Ratio of 2.5 to 3.5 was obtained. Warfarin was
continued for one month and aspirin indefinitely. In pa-
tients randomized to PTCA alone, oral aspirin was pre-
scribed, whereas heparin or warfarin was not.
Follow-up. According to the original protocol, a clinical
evaluation was performed at three, six, and nine months
after the procedure, and coronary angiography was sched-
uled at nine months. In addition, long-term follow-up was
obtained at the time of this analysis, by telephone interview,
or by direct visit. If the patient was rehospitalized, hospital
records were reviewed to assess the occurrence of clinical
events.
Angiographic analysis. Angiographic analysis was per-
formed at a central laboratory by quantitative coronary
angiography. Restenosis and reocclusion were respectively
defined as stenosis 50% of the lumen diameter at
follow-up and recurrence of total occlusion occurring at any
time after the procedure. The loss index was calculated as
the difference between post-intervention and follow-up
minimal luminal diameter divided by the post-intervention
minimal luminal diameter.
End points. The primary end point in this study was the
occurrence of major adverse cardiovascular events (MACE),
defined as cardiac death, any MI, and TLR with either
repeat PTCA or coronary artery bypass graft surgery
(CABG). Death was considered as cardiac unless otherwise
demonstrated. Myocardial infarction was documented by
the presence of new pathologic Q waves on the electrocar-
diogram, according to the Minnesota Code (11), or a rise in
creatine kinase of more than twice the upper normal limit.
The presence of anginal symptoms at follow-up was a
secondary end point. These symptoms were graded accord-
ing to the Canadian Cardiovascular Society classification.
The functional class was evaluated according to the New
York Heart Association guidelines (12). All evaluations
were performed according to the intention-to-treat princi-
ple, and in-hospital events were included in the analysis of
follow-up events. When more than one clinical event
occurred in a patient, the event occurring first was consid-
ered for survival analysis.
Statistical analysis. Categorical variables are expressed as
absolute numbers and percentage values. Continuous vari-
ables are expressed as the mean value  SD. Differences
between groups were assessed with a continuity-adjusted
chi-square test for categorical variables and with a two-
tailed unpaired Student t test for continuous variables.
Event-free survival rates were estimated using the Kaplan-
Meier method, with differences between the two treatment
groups assessed with the use of the log-rank test of signif-
icance. A p value 0.05 was considered statistically signif-
icant.
RESULTS
There were no significant differences in baseline clinical and
angiographic characteristics between the two study groups
(Table 1). Bleeding and vascular complications were more
frequent in the stent group (4.7% vs. 0%, p 0.11). At nine
months, patients in the PTCA group experienced a signif-
Abbreviations and Acronyms
CABG  coronary artery bypass graft surgery
CTO  chronic total coronary occlusion
GISSOC  Gruppo Italiano di Studio sullo Stent nelle
Occlusioni Coronariche
MACE  major adverse cardiac events
MI  myocardial infarction
PTCA  percutaneous transluminal coronary
angioplasty
TIMI  Thrombolysis In Myocardial Infarction
TLR  target lesion revascularization
Table 1. Baseline Clinical and Angiographic Characteristics
Stent Group
(n  56)
PTCA Group
(n  54)
Age (yrs) 58.3  6.8 57.0  9.3
Male 48 (86%) 45 (83%)
Previous MI 30 (54%) 45 (83%)
Previous CABG 1 (1.8%) 1 (1.8%)
Diabetes 6 (11%) 5 (9.2%)
Hypertension 22 (39%) 21 (39%)
Smokers 24 (43%) 23 (43%)
Hypercholesterolemia 25 (45%) 16 (30%)
Unstable angina 4 (7.1%) 6 (11%)
Estimated duration of
occlusion (weeks)
11.1  8.3 11.5  8.2
Multivessel disease 20 (36%) 12 (22%)
Occluded artery
LAD 29 (52%) 29 (54%)
LCx 7 (12%) 13 (24%)
RCA 20 (36%) 12 (22%)
Complete occlusion
(TIMI flow grade 0)
35 (62%) 38 (70%)
LVEF (%) 55.1  15.0 55.7  13.3
Data are presented as the mean value  SD or number (%) of patients. These data
were described in detail in the original publication of the GISSOC trial (5).
CABG  coronary artery bypass graft surgery; LAD  left anterior descending
coronary artery; LCx  left circumflex coronary artery; MI  myocardial infarction;
LVEF  left ventricular ejection fraction; PTCA  percutaneous transluminal
coronary angioplasty; RCA  right coronary artery; TIMI  Thrombolysis In
Myocardial Infarction.
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icantly higher rate of angiographic restenosis and reocclu-
sion of the treated lesion (Table 2).
Clinical follow-up was obtained after four years in all but
two surviving patients (98%). One patient in each treatment
group was lost to follow-up after the nine-month visit. The
follow-up time was 6.2  2.1 years.
Major adverse cardiac events. Table 3 summarizes the
events at nine months and six years. Events occurring during
the first nine months have been described in detail previ-
ously (5). Briefly, the TLR rate was significantly lower in
the stent group than in the PTCA group (5.3% vs. 22.2%,
p  0.038), whereas the other events were not significantly
different when individually analyzed.
Events occurring after the nine-month follow-up visit.
In the stent group, six deaths were observed: two were
caused by malignancy; two were sudden deaths; one was
caused by acute MI; and one patient died during a CABG
operation. In the PTCA group, there were two sudden
deaths. Two non-fatal MIs were observed in each group;
however, these events were not related to the study vessel.
Four patients (three in the stent group and one in the
PTCA group) underwent a CABG operation. One CABG
in the stent group did not involve the study lesion, which
was widely patent, whereas the CABG was a TLR proce-
dure in the other three cases. One of these patients died
shortly after the operation, as mentioned already. Repeat
PTCA was performed in 11 patients (6 in the stent group
and 5 in the PTCA group). Three repeat PTCA procedures
in the stent group did not involve the study vessel and were
motivated by progression of the disease in other vessels,
whereas the other eight were TLR procedures. Seven repeat
PTCAs (three in the stent group and four in the PTCA
group) were completed by stent implantation.
Overall, surgical or percutaneous TLR after nine-month
follow-up was performed in 11 patients. In 10 cases,
restenosis of the study lesion was evident at nine-month
angiography. The decision to perform a new revasculariza-
tion procedure after nine months was taken on clinical
grounds and was generally motivated by reoccurrence or
worsening of angina, together with progression of the
disease in other coronary vessels. In the remaining patient,
the status of the study artery at nine months was uncertain
because angiographic follow-up was refused; however, re-
stenosis of the study artery was documented and treated
with repeat PTCA three years after enrollment.
The estimated probability of freedom from MACE at six
years was 76.1% in the stent group and 60.4% in the PTCA
group (p  0.0555). This difference was essentially deter-
mined by a higher estimated six-year TLR-free survival rate
in the stent group (85.1% vs. 65.5% in the PTCA group, p
 0.0165). Kaplan-Meier analyses of freedom from MACE
and TLR are shown in Figures 1 and 2.
At the last follow-up interview, 76% of the surviving
patients were in New York Heart Association functional
class I, whereas the remaining patients (11 in the stent
group and 13 in the PTCA group) were in class II. At the
same time, 95% of patients had no angina, three patients in
the stent group were in angina class I, and one patient in
each group was in angina class III.
Table 2. Quantitative Coronary Angiographic Data
Stent
Group
PTCA
Group p Value
Postprocedural reference
diameter (mm)
3.01  0.48 2.92  0.55 0.34
Postprocedural minimal
luminal diameter (mm)
2.46  0.50 1.91  0.49  0.0001
Postprocedural diameter
stenosis (%)
18.2  11.2 34.5  10.3  0.0001
9-Month minimal luminal
diameter (mm)
1.74  0.88 0.85  0.75  0.0001
9-Month diameter
stenosis (%)
42.3  26.6 69.2  26.8  0.0001
9-Month restenosis
rate (%)
32.0 68.1 0.0008
9-Month reocclusion
rate (%)
8.0 34.0 0.0035
9-Month loss index 0.32  0.31 0.55  0.38 0.002
Data are presented as the mean value SD or percentage of patients. These data were
described in detail in the original publication of the GISSOC trial (5).
PTCA  percutaneous transluminal coronary angioplasty.
Table 3. Clinical Events During Follow-Up
0 to 9-Month Events* 6-Year Follow-Up Events†
Stent Group
(n  56)
PTCA Group
(n  54) p Value Stent Group PTCA Group
p Value
(Log-Rank)
Death, all causes 0 1 (1.8) 0.97 6 (11.2) 3 (5.7) 0.346
Death, cardiac 0 1 (1.8) 0.97 4 (7.7) 3 (5.7) 0.744
Non-fatal MI 0 0 — 2 (3.64) 2 (3.74) 0.963
CABG 2 (3.6) 4 (7.4) 0.74 5 (9.77) 5 (9.69) 0.957
Repeat PTCA 3 (5.3) 10 (18) 0.10 9 (17.2) 15 (28.6) 0.1344
TLR 3 (5.3) 12 (22) 0.038 8 (14.9) 18 (34.5) 0.0165
Cardiac death, MI, or TLR 3 (5.3) 13 (24) 0.012 13 (23.9) 21 (39.6) 0.055
*Data presented as the number (%) of patients. †Data presented as the number of patients (cumulative incidence). Six-year cumulative incidence (%) was estimated according
to the Kaplan-Meier product-limit method. In the stent group, three repeat PTCAs and one CABG occurring after 9 months did not involve the target lesion. Data on 9-month
follow-up were described in detail in the original publication of the GISSOC trial (5).
MACE  major adverse cardiac events (cardiac death, MI, TLR); TLR  target lesion revascularization; other abbreviation as in Table 1.
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DISCUSSION
This study represents the longest reported clinical follow-up
of patients treated with percutaneous recanalization of
CTO. Six-year follow-up data from the GISSOC trial
demonstrate that patients treated by either balloon PTCA
or stent implantation for CTO have a good prognosis, with
a low event rate. The incidence of cardiac death and the
incidence of non-fatal MI were similar in the two study
groups. The only significant difference in clinical events was
a lower TLR rate in patients assigned to stent implantation.
This difference was evident at nine months and remained
stable thereafter. The overall good long-term prognosis of
the patients in this study may be related to favorable
baseline clinical and angiographic characteristics. The pa-
tients were relatively young (mean age 58 years), with
preserved left ventricular function (mean ejection fraction
55%) and a low prevalence of established risk factors such as
diabetes (10%), unstable angina (9.1%), or previous CABG
(1.8%). In addition, 70% of patients had single-vessel
disease, and the occluded segment was relatively short (13
mm), suggesting non-extensive coronary atherosclerosis.
Moreover, only patients with successful PTCA were in-
cluded in the study.
During follow-up, four patients experienced a non-fatal
MI that was not related to the study artery. The relatively
low incidence of MI may be related to the high prevalence
of single-vessel disease, together with the fact that reocclu-
sion of recanalized CTO does not cause MI in the great
majority of cases (2,13).
Long-term follow-up of patients treated by balloon
PTCA or stent implantation. In patients with subtotal
stenosis treated by either balloon PTCA (14) or stent
implantation (15), repeated angiographic follow-up demon-
strated that the restenosis process generally takes place in
the first six months after the procedure and is very rare
thereafter. Consequently, the reported incidence of TLR
between one and five years is low, ranging between 2.1%
and 8.6% (15–18).
However, there are only limited data on long-term
clinical outcomes after percutaneous recanalization of CTO.
An early study (13) suggested that after balloon PTCA of
CTO, the detection of restenosis did not plateau at six
months, unlike that observed in subtotal stenosis, but
increased during two-year follow-up. This finding is incon-
sistent with our results and those of Sirnes et al. (19), who
reported follow-up after 2.7 years in patients treated with
PTCA or stent implantation for CTO. They found a 6.0%
rate of TLR procedures performed between 8 months and
2.7 years. Interestingly, all late TLRs occurred in patients in
the PTCA group, whereas none were observed in the stent
group (11.9% vs. 0%), although the reason for this difference
is unclear.
These rates of late TLR, as well as those reported in
patients with subtotal stenosis (15–18), seem to be some-
what lower than those observed in our study (10.9% in the
stent group and 11.3% in the PTCA group between 9
months and 6 years). However, in our study, almost all
restenoses were already detected on the nine-month angio-
gram. Therefore, late TLR events are not the consequence
of a delayed restenotic process but the result of a clinical
decision based on both coronary angiography and symptom-
atic status. In addition, a higher rate of TLR in our study
may be related to the longer follow-up in comparison to
other studies (15–19).
Study limitations. Because of the small sample size and
low rate of clinical events occurring during late follow-up,
this study does not have the power to detect potential
differences in the incidence of MACE between the two
study groups. In addition, only patients with a successful
balloon PTCA of CTO were included in the study, and
baseline clinical and angiographic characteristics indicated
that the study population was at relatively low risk.
The patients assigned to stent implantation were treated
Figure 1. Kaplan-Meier major adverse cardiac events (MACE)-free sur-
vival of patients assigned to stent implantation (solid line) or percutaneous
transluminal coronary angioplasty (PTCA) (dashed line). The number of
patients at risk for each time point is shown. MACE includes cardiac
death, myocardial infarction, or target lesion revascularization.
Figure 2. Kaplan-Meier target lesion revascularization (TLR)-free survival
of patients assigned to stent implantation (solid line) or percutaneous
transluminal coronary angioplasty (PTCA) (dashed line). The number of
patients at risk for each time point is shown.
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with a first-generation stent, with a low rate of high-
pressure stent expansion, which in turn led to a high residual
stenosis. In addition, they followed a suboptimal antithrom-
botic regimen (aspirin plus warfarin). These results may not
apply to a less selected population of patients treated with
more recent techniques, including the use of newer guide
wires for CTO, extensive reconstruction of occluded vessels
with long or multiple stents, high-pressure stent implanta-
tion, and aspirin plus ticlopidine therapy.
Conclusions. This study demonstrates that the major ben-
efit of stent implantation over balloon PTCA—a reduced
need for TLR—is maintained in the long term. Both the
PTCA and stent results appear to remain stable after
nine-month angiographic follow-up. Thus, stent implanta-
tion in CTO treated by percutaneous recanalization is a
valuable long-term therapeutic option.
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